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The Ewing Sarcoma Protein (EWS) Binds Directly to the
Proximal Elements of the Macrophage-Specific Promoter of the
CSF-1 Receptor (csf1r) Gene1
David A. Hume,2* Tedjo Sasmono,* S. Roy Himes,* Sudarshana M. Sharma,†
Agnieszka Bronisz,† Myrna Constantin,* Michael C. Ostrowski,† and Ian L. Ross*
Many macrophage-specific promoters lack classical transcriptional start site elements such as TATA boxes and Sp1 sites. One
example is the CSF-1 receptor (CSF-1R, CD115, c-fms), which is used as a model of the transcriptional regulation of macrophage
genes. To understand the molecular basis of start site recognition in this gene, we identified cellular proteins binding specifically
to the transcriptional start site (TSS) region. The mouse and human csf1r TSS were identified using cap analysis gene expression
(CAGE) data. Conserved elements flanking the TSS cluster were analyzed using EMSAs to identify discrete DNA-binding factors
in primary bone marrow macrophages as candidate transcriptional regulators. Two complexes were identified that bind in a
highly sequence-specific manner to the mouse and human TSS proximal region and also to high-affinity sites recognized by myeloid
zinc finger protein 1 (Mzf1). The murine proteins were purified by DNA affinity isolation from the RAW264.7 macrophage cell line
and identified by mass spectrometry as EWS and FUS/TLS, closely related DNA and RNA-binding proteins. Chromatin immu-
noprecipitation experiments in bone marrow macrophages confirmed that EWS, but not FUS/TLS, was present in vivo on the
CSF-1R proximal promoter in unstimulated primary macrophages. Transfection assays suggest that EWS does not act as a
conventional transcriptional activator or repressor. We hypothesize that EWS contributes to start site recognition in TATA-less
mammalian promoters. The Journal of Immunology, 2008, 180: 6733–6742.
M acrophages are a specialized lineage of hematopoieticcells with a distinct gene expression profile (1) re-quired to fulfil their many roles in innate immunity
(2). Their proliferation, differentiation, and survival are dependent
on the actions of the growth factor macrophage CSF-1, which acts
by binding to a specific receptor (CSF-1R, CD115) encoded by the
csf1r (c-fms) protooncogene. CSF-1R protein expression is re-
stricted to cells of the macrophage lineage, and a csf1r-EGFP
transgene provides a unique marker for cells of this lineage in mice
(3). Consequently, the transcriptional regulation of the csf1r gene
has been widely studied as a model for understanding the nuclear
events underlying macrophage lineage commitment (2, 4, 5).
The proximal promoter of the csf1r gene used in macrophages is
an archetype for a class of mammalian promoters that lacks con-
ventional proximal promoter elements such as a TATA box,
CCAAT box, or GC-rich elements bound by the transcription fac-
tor Sp1 (6, 7). Instead, it contains multiple copies of purine-rich
sequences recognized by members of the Ets transcription factor
family, notably the macrophage-specific transcription factor PU.1
(2). PU.1 is able to bind directly to components of the basal tran-
scription machinery such as TATA-binding protein (8–11), and a
multimerized PU.1 recognition motif can generate a minimal mac-
rophage-specific promoter (12). The activity of this artificial pro-
moter requires cooperation between PU.1 and another member of
the Ets family (12). Nevertheless, such a promoter is very weakly
active compared with the native csf1r proximal promoter in trans-
fections of macrophage cells, so we considered that PU.1 alone is
probably not the only DNA-binding protein required for start-site
specification in myeloid promoters. Furthermore, the functions of
a basal promoter are more complex than simple transactivation or
transrepression and include functions such as polymerase recruit-
ment and activation, transcription initiation and termination, the
regulation of splicing, histone positioning, and chromatin confor-
mation. In an attempt to further our understanding of the control of
csf1r transcription, we looked for additional proteins that bind spe-
cifically to the start-site region of the csf1r promoter.
In this paper, we have identified protein complexes that bind
related elements of the start-site region of both the mouse and
human csf1r promoters.
Materials and Methods
Cell culture
Cells were grown in RPMI 1640 medium (Invitrogen) supplemented with
10% (v/v) heat-inactivated FBS (BioWhittaker) and L-glutamine (2 mM,
GlutaMAX), 30 U/ml penicillin, and 100 g/ml streptomycin (all from
Invitrogen). Cells were maintained in a humidified tissue culture incubator
at 37°C in the presence of 5% CO2.
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Murine bone marrow-derived macrophages (BMM)3 were obtained by
differentiation of mouse bone marrow cells in the presence of 104 U/ml
human recombinant CSF-1 (Chiron). Briefly, adult mice (BALB/c or
C57BL/6) were culled by cervical dislocation and an incision was made
along the inner thigh of the hindlimbs. Each femur was exposed and re-
sected, after which the bone was sterilized and cleaned with 70% ethanol.
Dissected femurs were opened at both ends and the marrow cells were
flushed out with complete RPMI 1640 medium by the use of 27-gauge
needles fitted on 10 ml syringes. Cell clumps were disaggregated by pi-
petting up and down several times, and cell suspensions were grown in
tissue culture medium in the presence of CSF-1. On day 3 the medium was
changed and the culture was continued up to 7 days when typically 95%
of cells are macrophages (13). RAW264.7 cells were obtained from the
American Type Culture Collection.
Nuclear extraction
Nuclear extracts were prepared using a variation of the method described
by Osborn et al. (14). All solutions used were ice-cold and contained either
Complete Mini Protease Inhibitor Tablet (Roche Applied Science) or a
combination of 0.5 mM PMSF, 1 mM DTT, 1 g/ml aprotinin, and 1
g/ml leupeptin. For bulk preparation, adherent cells from six 10-cm-di-
ameter TC dishes were harvested and pooled in 50 ml polypropylene cen-
trifuge tubes. Cells were then pelleted at 400  g for 5 min at 4°C and
washed once with ice-cold PBS and once with hypotonic wash buffer
(buffer A) comprising 10 mM HEPES (pH 7.9), 10 mM KCl, 0.1 mM
EDTA, 2 mM MgCl2, and 0.1 mM EGTA. Washed cells were pelleted,
resuspended in 1 ml buffer A, and transferred to 10 ml tubes.
A 2-ml aliquot of cell lysis buffer (buffer B; 25 mM HEPES (pH 7.9),
10 mM KCl, 0.5 mM EGTA, 2 mM MgCl2, 0.2% Nonidet P-40) was added
at 4°C, mixed, and the nuclei were pelleted gently at 250  g for 10 min
at 4°C. Supernatants were removed and nuclei were extracted by resus-
pending in 500–750 l of nuclear extraction buffer (buffer C; 20 mM
HEPES (pH 7.9), 420 mM NaCl, 20% glycerol, 0.2 mM EDTA, 0.2 mM
EGTA). Nuclei were incubated in this buffer for 15 min on ice with gentle
shaking, followed by centrifugation of the extracts at 10,000  g for 10
min at 4°C. Supernatants were removed carefully, snap frozen in an eth-
anol/dry ice bath, and stored at 70°C.
For magnetic DNA affinity purification of DNA-binding proteins (see
below), large-scale nuclear extractions were performed from RAW264.7
cells. Typically, for one preparation, cells were harvested from 10 to 12
Sterilin 10 10 cm TC dishes. Depending on the number of cells obtained,
buffer A used was 4–5 ml, while buffers B and C were 2.5 and 1 ml,
respectively.
EMSA
Oligonucleotide probes for EMSA were prepared by end labeling 5 M
oligonucleotides with [-32P]ATP (10 mCi/ml, 3000 Ci/mmol) using T4
polynucleotide kinase (New England Biolabs) in 1 polynucleotide kinase
buffer for 30 min at 37°C. Unincorporated radionucleotides were removed
by passing the reaction through a Sephadex G25 column (NICK column,
Pharmacia). Radiolabelled probes were obtained by collecting 5-drop
(200 l) fractions. The radioactivity of the probe was monitored using a
Geiger-Mu¨ller counter, and the most radioactive void volume fractions
were then used in gel-shift experiments. Based on the shape of the elution
curve and the known amount of oligonucleotide loaded, the concentration
of probe in the peak fractions was estimated, assuming 100% recovery of
the oligonucleotides in the void peak.
Binding of nuclear proteins to the oligonucleotide was performed by
incubating 2 g or a 2-l aliquot of nuclear extracts, 0.5 g of poly(dI:
dC)(dI:dC) (Amersham Pharmacia Biotech), and 0.5 ng of end-labeled
double-stranded oligonucleotides in buffer containing 15% glycerol, 40
mM KCl, 20 mM HEPES (pH 7.9), 5 mM DTT, and 2 mM EDTA. The
reaction was incubated for 30 min at room temperature (RT). Supershift
experiments used 1 l of either anti-Ewing sarcoma (EWS) Ab (Santa Cruz
Biotechnology) or anti-FUS Abs, which were kindly provided by Dr. Mark
C. Alliegro (Department of Cell Biology and Anatomy, LSU Health Sci-
ences Centre, New Orleans, LA). Protein-probe complexes were separated
on a discontinuous 4–8% polyacrylamide gel system (29/1 polyacryl-
amide, 0.25 M Tris (pH 8.8)) in a Bio-Rad Mini Protean apparatus with
running buffer containing 25 mM Tris, 200 mM glycine, and 0.2 mM
EDTA. Samples were electrophoresed at 100 V until the loading dye
reached the bottom of the gel. Subsequently, gels were removed from the
apparatus, fixed in 10% acetic acid, dried into filter papers in a Bio-Rad gel
dryer, and exposed into Fuji Super RX X-Ray film for autoradiography.
Magnetic DNA affinity purification of csf1r promoter binding
proteins
RAW264.7 nuclear extract was diluted with binding buffer (10 mM
HEPES, 2 mM DTT, 0.5 g/ml aprotinin, 0.5 g/ml leupeptin, 10% glyc-
erol, 0.5 mM PMSF) to mimic the binding conditions used in EMSA/gel-
shift experiments. Subsequently, nonspecific protein-DNA binding was
blocked by addition of poly(dI:dC)(dI:dC) at 500 ng/ml and incubation for
5 min at RT. Meanwhile, streptavidin-coated paramagnetic beads (Dyna-
beads from Dynal Biotech, MagneSphere from Promega, or streptavidin
magnetic particles from Roche Applied Science) were washed from their
storage solutions with 1 binding buffer.
HPLC-purified biotinylated oligonucleotides were ordered from Gene-
Works. Before binding, biotinylated oligonucleotides (sense strands) were
annealed with their antisense strands by heating them at 65°C for 10 min
and incubating at RT for at least 10 min. Double-stranded oligonucleotides
were then bound to washed streptavidin-coated magnetic beads, with a
ratio of 1 mg particles to 120 M biotinylated oligonucleotides. Binding
was performed in 10 mM Tris-HCl at RT for at least 15 min with gentle
agitation in a rotary shaker. After binding, excess oligonucleotides were
washed away with 1 binding buffer before addition of nuclear extract.
DNA-binding protein isolation was performed by incubating the pre-
cleared nuclear extracts with the immobilized biotinylated oligonucleotides
in 15 ml tubes for 1 h at RT with gentle rotation of tube in rotary shaker.
After binding, reactions were transferred into 2 ml tubes and placed in
magnetic particle separator to capture the magnetic bead-oligonucleotide-
protein complex, and washed with binding buffer containing 50 mM NaCl
and 30 mM KCl. Four 1 ml washes were performed, and the bound proteins
were eluted with 200 l of 300 mM ammonium acetate (pH 4.2). Second
elutions were performed with 200 l of water. The eluted proteins were
concentrated by diluting the samples into 50 mM ammonium acetate with
MilliQ water followed by concentration in Microcon YM30 spin columns
(Millipore).
SDS-PAGE
Proteins were electrophoretically resolved using SDS-PAGE typically at a
gel concentration of 12%. The Bio-Rad Mini Protean apparatus was used
according to the manufacturer’s instructions. In some cases, proteins were
separated in precast 12% NuPAGE Bis-Tris gels (Invitrogen) in XCell
SureLock MiniCell apparatus (Invitrogen) using NuPAGE MOPS SDS
running buffer. The method used was as described by the manufacturer.
After separation, gels were fixed and stained with Coomassie brilliant blue
R250 (Sigma-Aldrich) diluted in methanol-water-glacial acetic acid (45/
45/10) for 30 min, followed by destaining of excess dye in 30% methanol-
10% acetic acid.
In-gel trypsin digestion of protein bands and mass spectrometry
For mass spectrometry analysis, protein bands of interest and blank gel for
controls were excised from the gel with sterile scalpel blades ready for
subsequent steps.
Excised gel slices were dehydrated in 100% methanol for 5 min fol-
lowed by rehydration in 30% methanol for 5 min. Rehydrated gel slices
were subsequently washed twice in ultrapure water for 10 min each. Each
gel band was then washed three times for 10 min each with 100 mM
ammonium bicarbonate (pH 7.5) containing 30% acetonitrile. After the last
wash, the gel was cut or crushed into small pieces, washed in ultrapure
water, and vacuum dried in a vacuum centrifuge for 30 min. Gel pieces
were then resuspended in 50 mM ammonium bicarbonate (pH 7.5) con-
taining 5–10 ng/l sequencing-grade trypsin (Promega) and incubated
overnight for 24 h at 37°C. The following day, supernatant was transferred
into fresh tubes and the remaining peptides in the gel were extracted with
50% acetonitrile containing 0.1% trifluoroacetic acid. This was combined
with the supernatant ready for mass spectrometry analysis, ensuring that
the final acetonitrile concentration was 5%.
A Hewlett-Packard 1100 HPLC system was used for liquid chromatog-
raphy separation. An aliquot (10 l) of peptide digest was injected onto a
Zorbax C18 reversed-phase HPLC column (2 mm internal diameter). Tryp-
tic peptides were eluted at 0.3 ml/min with a 0–45% gradient of acetoni-
trile with 0.1% TFA. The output stream was split 1:10 and peptides were
analyzed during elution by electrospray ionisation (ESI) quadrupole and
time-of-flight mass spectrometry (qTOF) in independent data acquisition
mode. Fractions were also collected and where required were loaded into
3 Abbreviations used in this paper: BMM, bone marrow-derived macrophage; CAGE,
cap analysis of gene expression; ChIP, chromatin immunoprecipitation; EWS, Ewing
sarcoma protein; FANTOM, functional annotation of mouse transcriptome project;
Inr, initiator; MS/MS, tandem mass spectrometry; RT, room temperature; TSS, tran-
scriptional start site.
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nanospray needles for analysis by direct nanospray ESI-qTOF mass spec-
trometry to obtain reliable peptide sequence for de novo sequence analysis.
Primary peptide sequence was deduced from tandem mass spectrometry,
and the National Center for Biotechnology Information (NCBI) protein se-
quence database was queried using the resultant peptide sequences to identify
candidate proteins with pBLAST (www.ncbi.nlm.nih.gov/BLAST/).
Transient transfection analysis
The preparation of transient and stable transfectants was conducted as pre-
viously described (15). Briefly, transfection was achieved by electropora-
tion of 5  106 cells in 400–450 l of RPMI 1640 medium buffered with
20 mM HEPES (pH 7.4) using a Gene Pulser electroporator (Bio-Rad) set
at 280 V with a capacitance of 960 F. For transient transfection, 10 g of
reporter plasmid was used, with 1 g of expression vector or control vector
(pEF6). For stable transfection, 8 g of reporter plasmid was used with 2
g of pPNT-neo (which confers resistance to neomycin). Immediately fol-
lowing electroporation, cells were diluted into complete medium, pelleted,
washed, and replated. For transient transfections, cells were harvested at
24 h for luciferase assays by briefly washing adherent cells with PBS
followed by lysis in 1 ml luciferase lysis buffer containing 500 mM
HEPES, 1 mM MgCl2, 1 mM DTT, and 0.2% Triton X-100 detergent. The
cellular debris was pelleted at 12,000 rpm and the supernatant retained for
assay using the LucLite reporter gene assay kit (Packard) according to the
manufacturer’s instructions. Light emission was measured with a Packard
TriLux luminometer and the output expressed as relative light units (RLU).
The protein concentrations of the lysate supernatants were measured with
the Bio-Rad protein assay using the manufacturer’s protocol.
Plasmid reporter constructs used in transfection analysis
Luciferase reporter constructs (0.3, 0.5, and 6.7 kb csf1r-luciferase) com-
prising portions of the murine csf1r promoter in pGL2 (Promega) were as
previously described (15, 16). Both substitution and deletion mutations of
the csf1r promoter were made in 0.5-kb csf1r-luciferase by splice overlap
PCR (17). The resultant plasmids were sequenced to check that the muta-
tions had been correctly made.
Plasmid expression constructs used in transfection analysis
Expression constructs for murine EWS and FUS/TLS were made in the
pEF6 vector (Invitrogen) by PCR amplification of murine cDNA using the
following primer sets: EWS: forward primer, 5-GAAGGGCGAGAAAAT
GGCGTC-3; reverse primer, 5-GTAGGGCCGGTCTCTGCGTT-3
(which excludes the natural stop codon so that the C-terminal V5-His tag
is enabled); FUS/TLS: forward primer, 5-TGCGCGGACATGGCT
TCAAA-3; reverse primer, 5-ATATGGCCTCTCCCTGCGATCCT-3.
Expression constructs in pEF6 were checked by sequencing to ensure
that they were correct.
Chromatin immunoprecipitation (ChIP) experiments
ChIP assays were performed as described earlier (18–20). Approximately
5  105 cell equivalents (one sixth) of the sheared soluble chromatin was
precleared with tRNA-blocked protein G agarose, and 10% of the pre-
cleared chromatin was set aside as an input control. Immunoprecipitation
was conducted with 5 g of Abs overnight at 4°C. The PU.1 Ab has been
FIGURE 1. CAGE tag analysis of murine and human csf1r proximal
promoters. The number of tags identified at a particular position corre-
sponds to the frequency of initiations at that position. The sequence shown
begins at120 (murine) or122 nucleotides (human) relative to the ATG
codon.
FIGURE 2. Alignment of the csf1r transcriptional start region in several vertebrate species. Only the major start sites are shown for human and mouse
genes. The shaded regions in the PU.1 binding region correspond to experimentally verified PU.1 binding sites (in mice and humans). In the initiation
region, shaded sections (regions 1–3) correspond to the EWS/TLS binding region, including the conserved AGCCAGTGC and GGAA motifs. The ATG
initiation codon in the first coding region is also shaded.
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described earlier (18). EWS Ab was purchased from Santa Cruz Biotech-
nologies, and rabbit polyclonal FUS Ab was purchased from Bethyl Lab-
oratories. Immune complexes were pulled down using protein G agarose
and washed, decrosslinked, and purified as described earlier (18).
Samples were analyzed by real-time PCR with a probe sequence derived
from the Roche universal probe library (Roche Diagnostics) using the Fast-
Start TaqMan master kit (Roche). Primers for the probe were 5-GGGCA
GATGAGAAAGGTATGA-3 (forward) and 5-AGTCTCCCAGAT
GAGCAGTGA-3 (reverse), which generate a 77-bp amplicon across the
csf1r promoter. The thresholds for the promoters being studied were ad-
justed using input threshold values as reference values and are represented
as relative enrichment.
Results
Determination of the in vivo start site in the mouse and human
csf1r genes
Recent data produced by the FANTOM3 (functional annotation of
mouse transcriptome project 3) consortium has provide a unique
resource for precise annotation of start site usage in the mouse and
human genes based upon cap analysis gene expression (CAGE)
technology (6) (fantom.gsc.riken.go.jp). In both mouse and human
csf1r genes, transcription initiates in a relatively broad region cov-
ering 30–50 bp. The transcription start site (TSS) in both genes
was previously determined using reverse transcriptase primer ex-
tension or RNase protection, neither of which had perfect base pair
accuracy or the quantitative data to identify relative start usage in
a range of conditions. For the CAGE analysis in the mouse, some
20 separate libraries derived from BMMs cultured with a range of
stimuli were polled. A comparative analysis of the CAGE tag dis-
tribution for the mouse and human promoter regions is shown in
Fig. 1. The data for the mouse are not completely consistent with
previous data based on primer extension (16), probably due to the
use of a primer that was too close to the 5 end based upon the
longest cDNA sequence then available. However, the original data
based upon RNase protection (16) was found to be completely
consistent with the CAGE pattern shown. Close examination of the
major start sites reveals that they all conform to pyrimidine/purine
initiator core sequence, mostly the preferred CA, as in most mamma-
lian promoters (6). The sequence surrounding this is more variable;
that is, no site conforms to the initiator (Inr) consensus YYANWYY,
although the major start site in mice and one of the human major sites
conform in at least four of the six positions.
A comparison of promoters from different species (Fig. 2)
shows that the human sequence is ancestral and a deletion has
occurred in the rodents that removes one PU.1 site. The deletion
actually shifts the upstream PU.1 site into the same position (rel-
ative to the transcription start sites) as the one that was removed.
The basic promoter structure is conserved throughout the mam-
mals, and Follows et al. (21) have demonstrated that the overall
chromatin organization of the murine and human promoters is also
conserved. Even Xenopus (Ensembl ENSXETG00000011887) ap-
pears to have a similar structure including a purine-rich promoter
and, based on the mRNA from NCBI (NM_001008180), a similar
transcript initiation site to the murine and human promoters.
FIGURE 3. A nuclear DNA binding complex is observed for both mu-
rine and human csf1r promoter sequences. EMSAs of the murine (A) and
human (B) promoter sequence are shown immediately upstream of the
main transcriptional initiation sites using BMM nuclear extract. The highly
conserved CCAGTG motif is shown in boldface type (C). A pair of pro-
tein-oligonucleotide complexes with identical mobility are present with
both murine and human oligonucleotides (arrowed). These complexes are
competed by cold self oligonucleotide (100 molar excess) and are cross-
competed by the alternate species, indicating that this region of the human
and murine promoter sequences binds the same protein(s).
FIGURE 4. The conserved csf1r promoter region is not an E box. A,
EMSA of labeled human csf1r oligonucleotide in the presence of cold
competitors comprising a series of oligonucleotides containing E box mo-
tifs similar to the highly conserved CCAGTG motif in the csf1r promoter.
Using BMM nuclear extract, the previously observed csf1r promoter
binding complexes are effectively competed by a 100 molar excess of
self oligonucleotide. B, Although a mutation in the putative E box
(CCAGTG3CTTGTA) in the murine csf1r promoter abolishes competi-
tion by the murine sequence, a series of known E box motifs at 100molar
excess also fail to compete, suggesting that the observed complexes are not
due to known E box binding proteins present in macrophages.
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Conserved motifs exist upstream of the transcription initiation
sites
In earlier studies, we mutated the sequence CAGGAA from the
promoter on the presumption that it was centrally placed within the
TSS region. The mutation abolished proximal promoter activity in
transfected macrophage cell lines (12). Tagoh et al. (22) showed
that during macrophage differentiation from progenitors, this site
becomes hypersensitive to modification by dimethyl sulfate as de-
tected by in vivo footprinting. The site was mistakenly annotated
as a PU.1 binding site, but it does not bind PU.1 in either EMSA
or DNase protection assays (12). The CAGE (and RNase protec-
tion data) reveals that this motif is actually immediately upstream
of the major start sites, where the preinitiation complex must as-
semble. The in vivo dimethyl sulfate footprinting data of Tagoh
et al. (22) actually revealed macrophage-specific hyperreactive
G(N7) sites extending from the CAGGAA motif upstream through
the sequence GCCAGTGCAACAGACAGGAAA (Fig. 2). As
well as the conserved Ets-like motif GGA(A/G), this upstream
sequence contains a motif AGCCAGTG that is conserved between
the murine and human promoters, as well as widely in other
species (Fig. 2, region 1). This motif (which resembles an E box
consensus CANNTG) is immediately (20–30 bp) upstream of the
cluster of start sites in humans and mice in a region that might be
considered to function like a TATA box. Given the evidence that
the site is specifically occupied in macrophages, we set out to
identify the proteins that bind to it.
EMSA of macrophage nuclear proteins binding the mouse and
human csf1r proximal promoter motifs
To determine whether macrophages contain nuclear DNA binding
proteins that can bind the csf1r proximal promoter element imme-
diately adjacent to the TSS region, and to confirm the functional
equivalence of the mouse and human proximal promoter regions,
we performed EMSAs using nuclear extracts from murine BMM.
As shown in Fig. 3, both the mouse and human elements bound to
a broad doublet on EMSA that was cold-competed by either self or
by the corresponding site from the other species. These cannot be
Ets proteins. In considering candidate proteins that might bind this
sequence, we examined the possibility that the CCAGTG sequence
of interest could constitute a variant E box, because macrophages
express several members of the basic helix-loop-helix transcription
factor family (23). Fig. 4 shows that several sequences from other
myeloid promoters that contain this CCAGTG sequence failed to
cold compete against the human csf1r probe; however, mutation of
the core CCAGT to CTTGA in the mouse sequence reduced cold
competitor activity, arguing that this motif does form part of the
murine recognition sequence. We therefore searched across the
entire mouse sequence using single base pair substitution, but did
not identify any single substitution that abolished binding activity
(data not shown). Fig. 5 shows the results of mutating bases from
the murine csf1r TSS-flanking element three at a time. Paradoxi-
cally, in this particular series, the substitutions chosen over the
CCAGTG motif (mutants 1–3) competed effectively, suggesting
that these mutant oligonucleotides still bound the factor(s) con-
cerned. In contrast, the next three downstream triplet substitutions
(mutants 4–6) failed to compete. Finally, mutant 7 competes suc-
cessfully, demonstrating that the binding site is confined to the
region specified by mutants 4–6. Overall, this suggests that the
protein(s) concerned require both the CCAGTG (region 1) motif
and the downstream CAACAGACA (region 2), but that the triplet
substitutions made in the CCAGTG motif still allow binding, un-
like the TT-A substitution made earlier (Table I).
Finally, we noted a similarity between the human and mouse
elements and the rather loose consensus of the so-called X box
FIGURE 5. Mutational analysis reveals the binding site for the csf1r
binding complexes includes the region CAACAGACA. A, EMSA was con-
ducted using labeled wild-type murine csf1r oligonucleotide and BMM
nuclear extract. Cold competition was conducted with oligonucleotides
comprising a series of mutations across the sequence, extending farther
than the conserved CCAGTG motif. Only mutants 4, 5, and 6 failed to
compete, suggesting that the sequence in this region (as well as the pre-
viously identified TT mutant) was important for binding. B, Sequences of
the mutated oligonucleotides used for competition experiments.
Table I. EMSA competition by mutations around the conserved CCAGTG motif a
Oligonucleotide Sequence 5 to 3 Experimental Result
GAGGAGCCAGTGCAACAGACAGGAAC Wild type: competes
GAGGAGCTTGTACAACAGACAGGAAC Fig. 4 mutant: fails to compete
GAGTTTCCAGTGCAACAGACAGGAAC Fig. 5 mutant 1: competes
GAGGAGAATGTGCAACAGACAGGAAC Fig. 5 mutant 2: competes
GAGGAGCCATGTCAACAGACAGGAAC Fig. 5 mutant 3: competes
GAGGAGCCAGTGACCCAGACAGGAAC Fig. 5 mutant 4: fails to compete
GAGGAGCCAGTGCAAACTACAGGAAC Fig. 5 mutant 5: fails to compete
GAGGAGCCAGTGCAACAGCACGGAAC Fig. 5 mutant 6: fails to compete
GAGGAGCCAGTGCAACAGACATTCAC Fig. 5 mutant 7: competes
a Conserved motif boxed; mutated base pairs are shaded gray.
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(24) that binds members of the RFX transcription factor family,
but none of a series of known functional X box motifs (Table II)
showed any ability to cold compete with the human probe (data not
shown). Based on all of these findings, the binding activity of the
macrophage nuclear proteins that recognize the mouse and human
csf1r proximal promoters is highly sequence-specific and involves
residues spaced over 9–12 bp pairs, any one of which can be
substituted without dramatically reducing binding activity.
Purification and identification of the csf1r proximal promoter
binding proteins
To directly identify the proteins that bind the TSS-flanking ele-
ment of the proximal promoter of the csf1r promoter, we per-
formed oligonucleotide affinity chromatography on RAW264.7
nuclear extracts, using murine csf1r oligonucleotides that were 5
biotinylated and immobilized on streptavidin-coated paramagnetic
beads. Two major bands (apparent molecular masses of 70 and 110
kDa) were identified reproducibly on Coomassie-stained gels (Fig.
6A) with two separate, overlapping oligonucleotides, and were ex-
cised and subjected to protein identification by tandem mass spec-
trometry. Using de novo tandem mass spectrometry (MS/MS) se-
quencing in addition to peptide mass fingerprinting, the two
proteins were identified unequivocally as FUS/TLS and the closely
related EWS protein (Table III).
The use of overlapping but slightly displaced probes (containing
regions 1  2 and 2  3) suggested that EWS binds preferentially
to the distal (3) site (perhaps requiring some downstream se-
quence in addition to the G-rich region), while FUS/TLS binds
equally well to both probes, presumably in the overlapping region.
PU.1 bound only to the X box oligonucleotide that contains the
known PU.1 site. To confirm the identity of these proteins as the
major bands seen on EMSA, we performed Ab supershift experi-
ments. Abs against either EWS or FUS/TLS generated a super-
shifted complex in macrophage nuclear extracts (Fig. 6B) and the
amount of supershifted complex increased with the amount of nu-
clear extract added. EWS and FUS/TLS are both known primarily
as RNA-binding proteins. To our knowledge, EWS has not previ-
ously been shown to bind to double-stranded DNA, but FUS/TLS
was previously discovered as downstream target of the bcr-abl
oncogene, based upon affinity purification using a consensus zinc
finger oligonucleotide that is bound by the myeloid zinc finger
protein Mzf-1 (25, 26). Accordingly, we performed EMSA using
the same consensus zinc finger oligonucleotide, termed ZnSab, as
a competitor (Fig. 7A). Using as a probe the same csf1r “X box”
oligonucleotide, both unlabelled self oligonucleotide and the
ZnSab oligonucleotide competed with the csf1r DNA-binding
complexes seen in Fig. 5, while, as before, excess mutant oligo-
nucleotides failed to compete. In the reverse experiment (Fig. 7B),
proteins binding to labeled ZnSab oligonucleotide were cross-
competed by unlabelled csf1r X box oligonucleotide as well as by
unlabelled ZnSab. These experiments suggest that the same com-
plexes bind to the csf1r promoter and to ZnSab. The ZnSab se-
quence, 5-CATCTAAAGTGGGGAGAAA-3, cannot obviously
be aligned with the mouse and human csf1r sequences, but the
finding that this oligonucleotide competes for binding to those se-
quences suggests that binding is mediated through the C-terminal
zinc fingers that are shared by EWS and FUS/TLS and that for
FUS/TLS has been demonstrated to be the DNA binding domain
(27) in the case of the ZnSab sequence.
Functional significance of binding to the TSS-flanking element
Both EWS and FUS/TLS mRNAs are expressed at high levels in
murine BMM compared with other tissues based upon Affymetrix
cDNA microarray profiling (symatlas.gnf.org), a finding that we
have confirmed by quantitative real-time PCR analysis (not
FIGURE 6. A, The 12% SDS-PAGE separation of proteins binding to
double-stranded overlapping murine csf1r promoter oligonucleotides,
stained with Coomassie blue. The “X box” oligonucleotide included the
adjacent 5 PU.1 site and had the sequence 5-GGGGAAGAGGAGCCA
GTGCAACAGACAGGAAC-3. The “Inr/Ets” oligonucleotide started
partway through the conserved CCAGTG motif but extended farther down-
stream and had the sequence 5-AGTGCAACAGACAGGAACGTGTT
CAT-3. Of the arrowed bands, the upper was identified by mass spectros-
copy as EWS, the lower as FUS/TLS. The band marked by the asterisk was
identified as PU.1, which is known to bind the csf1r promoter. B, Ab
supershift EMSA using BMM nuclear extracts following identification of
EWS and FUS/TLS as proteins that bind the csf1r oligonucleotide. The
major (lower) band is the normal EMSA complex; the probe has been run
off the gel to enable greater separation of the complexes. The experiment
was conducted with either 0.2 or 1.0 g of nuclear extract. In comparison
to the control lanes lacking Ab, addition of anti-EWS or anti-FUS/TLS Abs
(1 l in every case) produced a supershifted band (arrowed) on EMSA. The
intensity of the supershifted band increased as more nuclear extract was
added.
Table II. X box sequences used in competition EMSA experiments against the human csfr1 putative X box
Sequence Origin
AACAAGACAAACAGCCAGTGCAGAGG Human csf1r promotera
NNGTNRCCNNRGYAACNN RFX consensus
TCCCCTAGCAACAGATGCGT DRA X box
GATCTGAGTAGTTATGGTAACTG MIE c-myc X box
GATCCGTTGCTCGGCAACGGCCTA Hepatitis B X box
CTGCCCAGAAACAAGTGATG Li promoter X box
CAGTGTTGCCTAGGAGACAG IL5 promoter X box
CCCTAGCAACAGATGCG RFX1 consensus
a Probe sequence against which competition was performed.
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shown) and by the presence of sufficient protein to be isolated for
mass spectrometric identification (Fig. 6A) and EMSA assays.
FUS/TLS has been knocked out in the mouse germline, and the
mutation is neonatal lethal (28). A defect in B lymphocyte devel-
opment was observed, but pre-B cells from knockouts differenti-
ated normally after transplantation into a wild-type background.
The authors claim there was no myeloid phenotype (28), but the
data actually show that the number of monocytes in peripheral
blood was substantially reduced. In fact, the FUS/TLS mutant phe-
notype is not dissimilar to the selective monocyte and B lympho-
cyte depletion that is observed in csf1r/ mice (29). In contrast,
the EWS knockout (30) displays a cell-autonomous loss of B lym-
phocytes, but like the FUS/TLS knockout, has defects in meiosis.
Although both FUS/TLS and EWS can specifically bind the csf1r
proximal promoter, we were interested to identify whether these
factors were present at the csf1r locus in vivo in unstimulated
primary cells (BMMs). We conducted chromatin immunoprecipi-
tation experiments for EWS, FUS/TLS, as well as for PU.1. Fig. 8
demonstrates the presence of EWS and (as expected) PU.1 but not
FUS/TLS at the csf1r locus in BMMs. Given that FUS/TLS is
expressed in BMM and is clearly capable of binding the promoter
in a cell-free system, this interesting result suggests that some
mechanism intrinsic to the promoter architecture prevents the
binding of FUS/TLS to the proximal promoter, at least in
unstimulated BMMs.
Both FUS/TLS and EWS have multiple interaction partners and
roles in basal transcription and RNA processing. Furthermore,
both have powerful activation domains, and EWS at least can act
as a transcription factor in some circumstances (31). Using trans-
fection analysis, we examined the possibility that by overexpres-
sion of these proteins in both macrophage and nonmacrophage cell
types we could demonstrate them acting as transcription factors or
repressors on the csf1r gene. We transfected NIH3T3 cells with a
0.3-kb csf1r-luciferase reporter plasmid simultaneously with either
full-length EWS or full-length FUS/TLS expression vectors. In
these cells, we found modest effects of overexpression. EWS re-
pressed csf1r reporter activity about half, whereas FUS/TLS pro-
duced a 2-fold activation (Fig. 9). Coexpressing PU.1 did not affect
the pattern of results. In contrast, in RAW264.7 macrophage cells
with various full-length or truncated forms of EWS or FUS/TLS,
we observed no significant effect on the activity of a cotransfected
csf1r proximal promoter construct (data not shown). Although this
suggests that EWS and FUS/TLS are incapable of acting as tran-
scription factors in this context, we cannot rule out the possibility
that the promoter architecture is already established by endoge-
nous proteins so that overexpression contributes no additional ef-
fect. Furthermore, because RAW264.7 is a virally transformed cell
line, it is possible that the results may reflect the transformed state
of the cell, rendering it a poor model for primary macrophages in
this instance.
We turned next to mutations of the promoter region to look at
the role of each element. Mutation of the core CAGGAA (region
FIGURE 7. The csf1r promoter DNA binding complexes are competed
by the known FUS/TLS binding sequence ZnSab, and complexes observed
on the ZnSab oligonucleotide are cross-competed by the csf1r sequence. A,
EMSA using BMM nuclear extract and labeled murine “X box” csf1r
probe. The csf1r-binding complexes identified in Fig. 5 and that fail to be
competed by a 100 molar excess of mutants 4 and 5 are effectively
competed by a 100 molar excess of ZnSab, which contains a known
FUS/TLS binding site. B, EMSA using BMM nuclear extract and labeled
ZnSab probe. A ZnSab binding complex (presumably FUS/TLS) running
in approximately the same location as the csf1r-binding complexes is ef-
fectively competed both by unlabelled ZnSab and by a 100 molar excess
of unlabelled murine X box csf1r oligonucleotide.
FIGURE 8. Chromatin immunoprecipitation indicates that EWS, but
not FUS/TLS, is present at the csf1r promoter. A, Immunoprecipitation
from BMM chromatin of both EWS and of the known csf1r-binding pro-
tein PU.1 reveals coprecipitation of the csf1r promoter. Immunoprecipita-
tions from the same extracts using anti-FUS/TLS Abs, or control IgG, fail
to precipitate the csf1r promoter. B, The amplicon used for chromatin im-
munoprecipitation experiments.
Table III. EWS and FUS/TLS peptides identified by MS/MS
Band Peptide m/z (ESI) Charge MS/MS Sequence Obtained Assignment Corresponding Protein Sequence
A 713.34 2 PM(L/I)N(L/I)YTDR FUS/TLS TGQPMINLYTDR
A 512.25 2 AA(L/I)DWFDGK FUS/TLS AAIDWFDGK
B 603.27 2 PGP(L/I)MEQMGG EWS PGPLMEQMGG
B 512.25 2 AAVEWFDGK EWS AAVEWFDGK
B 833.02 3 YGQESGGFSGPGENR EWS QDHPSSMGVYGQESGGFSGPGENR
, methionine sulfoxide.
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3) motif, which occurs at the very 3 end of the putative EWS and
FUS/TLS site, ablates promoter activity in RAW264 macrophages
(12), a finding that was reconfirmed here (data not shown). To
further delineate the function of the FUS/TLS/EWS element, we
made a number of other substitution mutations in the 0.5-kb csf1r
promoter-luciferase reporter constructs. These mutant reporter
plasmids were stably transfected into RAW264 cells. To avoid the
inherent variation in single clones, pools of stable transfectants
were assayed for luciferase activity. As shown in Fig. 10, mutation
of the E box-like motif, CCAGTG, to CTTGTA caused a minimal
reduction in promoter activity in stable transfectants. Mutation of
the central triplet of the core EWS and FUS/TLS binding site
(CAACAGACA) to CAAACTACA, which greatly reduced bind-
ing in the cold competition assays, caused 50% reduction of
promoter activity. A series of deletions in the CAACAGACA re-
gion (Fig. 11) also caused modest reductions in promoter activity
in transient transfection assays. Given the fact that no single point
mutation abolishes binding, the size of the motif, the potential for
tethering these proteins to PU.1, and the fact that the zinc finger of
these proteins is only likely to contact 3–4 bp, it is unlikely that
any of these mutations completely abolishes EWS binding to the
transfected promoter. Taken together, the data support the view
that this element normally forms part of the csf1r proximal pro-
moter complex.
Discussion
We have shown that the RNA binding zinc finger proteins EWS
and FUS/TLS bind to positionally equivalent elements of the
mouse and human csf1r promoters, located immediately upstream
of the major transcription start sites, and that in vivo, EWS at least
is present on the csf1r promoter. The extensive cold-competition
studies indicate that binding is sequence-specific. It is formally
possible that the band seen in our EMSA assays consists not of
EWS and FUS alone, but of a complex of EWS or FUS with
another protein that is actually responsible for the DNA-binding
activity. We regard this as unlikely because the behavior of the
EMSA complexes on the ZnSab probe (which is known to bind
monomeric FUS/TLS directly) is similar to those on the csf1r
probes, and because no other protein was seen in stoichiometric
amounts on SDS-PAGE of the DNA binding complexes isolated
specifically on the csf1r oligonucleotides (Fig. 6). We confirmed
the earlier observation that, in vitro, FUS/TLS binds to the con-
sensus binding sites for the myeloid zinc finger protein, Mzf1, and
we extended the finding to EWS. This observation suggests that
the binding is mediated by the zinc fingers, as previously inferred
(27). Given the size of the binding site (11 bp) compared with the
4–5 bp required for Mzf1 binding (see www.jaspar.com), and the
FIGURE 9. Transient transfection analysis in NIH3T3 (fibroblast) cells
of the effect of full length wild-type EWS or FUS/TLS expression con-
structs on a 0.3-kb csf1r-luciferase reporter construct. Luciferase activity
(SEM) is shown for duplicate transfections. The micrograms of either
pGL2-Basic (control) or 0.3-kb csf1r-luciferase (test) reporter plasmid was
transfected along with 2 g of expression plasmid. Empty pEF6 vector was
used as a control where no expression plasmid was used. Transfected cells
were cultured for 24 h before being harvested and assayed for luciferase
activity. A PU.1 expression vector was included to test for PU.1-dependent
effects of EWS and/or FUS/TLS.
FIGURE 10. A, Stable transfection analysis of wild-type or mutated
0.5-kb csf1r-luciferase reporter constructs in the RAW264.7 macrophage
cell line. Ten micrograms of reporter plasmid was transfected in the pres-
ence of 2 g pMC1Neo resistance plasmid, and pools of stable transfec-
tants were selected for 7 days with G418 as reported in Methods and
Materials. Equivalent cell numbers of the pooled stables were then plated
overnight and assayed for luciferase activity. The results shown are the
means of two independent experiments performed in triplicate, with the
range of the data varying by 10% from the means. B, Mutations in
the promoter region of the transfected luciferase reporter constructs.
FIGURE 11. A, Transient transfection analysis in RAW264.7 (macro-
phage) cells of deletion mutations of the putative X box region immedi-
ately upstream of the transcription start sites of the csf1r promoter. Lucif-
erase activity (SEM) is shown for duplicate transfections. Reporter
plasmids (10 g) comprising either wild-type or mutant promoters were
transfected into RAW264.7 and the cells harvested at 24 h before being
assayed for luciferase activity. B, Deletions in the promoter region of the
transfected luciferase reporter constructs.
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fact that no single base pair change abolishes binding, there may be
multiple binding sites for the two factors in the csf1r proximal
region. ChIP experiments show that in vivo, EWS but not FUS/
TLS is present at this locus, a surprising result given that the
known interactions with PU.1 would be expected to preferentially
stabilize FUS/TLS binding. Although an interaction between EWS
and PU.1 is not impossible, it has not been reported to date. It may
be that PU.1 has another partner in vivo that actually excludes
FUS/TLS binding in resting (unstimulated cells) and that in some
other situations FUS/TLS binding is enabled. Alternatively, the
FUS/TLS binding site may be obscured in vivo in some other way.
Naturally, until the csf1r locus is examined by ChIP under a wider
range of conditions, it is impossible to formally exclude a role for
FUS/TLS as well as EWS at this promoter.
Part of the reason that interactions of PU.1 with FUS/TLS are
known is that FUS is commonly associated with translocations in
myeloid leukemias (32). In general, tumor-promoting fusions of
both FUS and EWS involve the association of the N-terminal
trans-activation domains with DNA-binding domains of classical
transcription factors, notably members of the Ets family. Such fu-
sions might bring together in a single molecule activities that are
normally contributed separately to myeloid promoters. Alterna-
tively, the fusion proteins might interfere with optimal transcrip-
tion or processing of genes such the csf1r, which are required for
terminal myeloid differentiation. If Mzf1, FUS/TLS, and EWS
bind to similar DNA sequences, there is the formal possibility that
like Pax5, Mzf1 (and possibly related C2H2 zinc finger proteins
such as PML and the Gli1 family (33, 34)) would act as a repressor
of myeloid-specific transcription by competing directly for binding
to this important proximal promoter element. Mzf1 is expressed in
pluripotent stem cells and early myeloid progenitors, but it is ab-
sent from mature myeloid cells. The decline in Mzf1 with myeloid
lineage commitment could permit activation of promoters like that
of the csf1r. The knockout of Mzf1 in mice does, indeed, lead to
a myeloid hyperproliferative syndrome (35). In a similar vein,
Tagoh et al. (36) recently showed that Pax5, which represses csf1r
expression in B cells, does so by directly binding to the AGTG
CAACAGACAGGAACGTG element of the csf1r promoter, im-
mediately displacing RNA polymerase II while still permitting
PU.1 binding. Although these authors suggested that Pax5 would
disrupt the interaction between PU.1 and the transcription initia-
tion complex, our results suggest that it could also act by abrogat-
ing binding of EWS to this site.
Both EWS and FUS/TLS are TATA-associated factors (there is
a third family member, TAF15, which was not detected in this
study). Each of these factors has a powerful N-terminal transacti-
vation domain that can bind to the Zfm1 (or Sf1) protein. There is
evidence that the proteins are associated with separate pools of
TFIID and with the RNA polymerase II holoenzyme (37). Thus,
given this ability, and the location of the binding sites on the pro-
moters, we propose that EWS essentially substitutes for TATA-
binding protein and serves a similar function to Sp1 on GC-rich
TATA-less promoters (38). In fact, this role of EWS (and/or FUS/
TLS) could be a more general feature even of the CpG-rich class
of TATA-less promoters. The systematic analysis of start sites by
CAGE in the FANTOM3 project revealed substantive G anisot-
ropy (i.e., enrichment of Gs on the upper strand) within CpG island
promoters, which is the major promoter class in the mammalian
genome (6).
It is clear that different promoters use different sets of basal
transcriptional factors in addition to the general transcription fac-
tors (7). For example, TBP is not essential for TATA-less promot-
ers (39). In contrast, TIC-2 and TIC-3 (incompletely characterized
TATA/Inr cofactors) are necessary for the in vitro reconstitution of
transcription from TATA-less promoters (40). These factors have
yet to be identified but clearly TLS/FUS and EWS are candidates
for these or similar activities. Interestingly, Martinez et al. (40)
who described TIC-2 noted that one component of the fraction is
TAF15 (TFII68), which is the third member of the EWS family.
EWS and FUS/TLS are remarkably multifunctional proteins,
with clear examples of specific roles in transcription, splicing, and
RNA transport. To date, FUS/TLS has been ascribed the greatest
diversity of roles. Despite the close similarity between the two
molecules, clear structural and functional differences exist. For ex-
ample, FUS/TLS (but apparently not EWS) is associated with traf-
ficking RNA to dendritic spines (41–43) or focal adhesions (44),
while most specific interactions with splicing or transcription fac-
tors have been described for either FUS/TLS or EWS but not
for both.
The final question arising from our data is therefore whether the
functions of the two proteins on myeloid promoters can be redun-
dant, especially because the EWS knockout does not lead to a
depletion in the myeloid cell population (30). Because of the rel-
atively loose binding specificity and propensity for poly(G) bind-
ing, protein-protein interactions are likely to play a role in the
specificity of association of EWS and FUS/TLS with the csf1r
promoter. FUS/TLS has been shown to bind and regulate functions
of PU.1, including splicing (45, 46), so there is a clear possibility
of functional interactions between the two proteins on myeloid
promoters, especially because on the csf1r promoter it is FUS/TLS
that appears to bind immediately downstream of the PU.1 site. In
contrast EWS, but not FUS/TLS, contains an RNA polymerase
II-like domain. In the case of the EWS-WT1 fusion, this region is
capable of being phosphorylated by Abl kinases, leading to the
initiation of paused transcriptional complexes (47). Whether this
occurs with native EWS is not known.
Although we favor a role for EWS in transcriptional initiation,
it could alternatively contribute to splicing and/or transcriptional
elongation. It might also participate in the phenomenon of exon
tethering (48) through its dual RNA- and DNA-binding abilities.
The clear evidence of specific binding to the TSS provides the
basis and impetus for future mechanistic studies.
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